A project led by Dr. Sedat Gökmen at Kastamonu University, titled "In Vivo and In Vitro Investigation of the Protective Effects of Melittin Against Doxorubicin-Induced Cardiotoxicity," has been awarded support under the TÜSEB Group A Urgent R&D Project Support Program.
The project aims to explore the protective effects of melittin, derived from honey bees (Apis mellifera), against the cardiotoxicity caused by doxorubicin, a widely used cancer treatment drug. This study, which will involve both cell culture and animal experiments, seeks to contribute to the development of new and alternative strategies to mitigate the side effects of drugs used in cardiotoxicity.
The 12-month project will be conducted under the leadership of Dr. Sedat Gökmen from the Department of Pharmacology and Toxicology, with collaboration from researchers from various disciplines, including Assoc. Prof. İrfan Çınar, Assoc. Prof. Musa Tatar, Dr. Muhammed Etyemez, Dr. Çiğdem Sevim, and Dr. Serdar Akyel.
In a statement, our Rector, Prof. Dr. Ahmet Hamdi Topal, emphasized that such projects not only enhance the university's scientific research capacity but also offer significant opportunities to address health-related challenges in our country. He expressed his appreciation for the efforts of the academics involved in the project, who are seeking natural solutions to cardiotoxicity, and wished them continued success.
Our Rector also extended his gratitude to the President of the Council of Higher Education, Prof. Dr. Erol Özvar, and the members of the Council for their support of high-quality and impactful research. He also thanked TÜBİTAK President Prof. Dr. Orhan Aydın for his encouraging approach to institutional research efforts.
